Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study Yasenchak, C. A., Halwani, A., Advani, R., Ansell, S., Budde, L., Burke, J. M., Farber, C. M., Holkova, B., Fayad, L. E., Kolibaba, K. S., Knapp, M., Li, M., Manley, T. J., Patel-Donnelly, D., Seetharam, M., Yimer, H. A., Bartlett, N. L. AMER SOC HEMATOLOGY. 2015

View details for Web of Science ID 000368019002251